Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples